This single-center observational study aimed to evaluate the accuracy of LDH, Ferritin, and D-Dimer levels as early predictors of mortality in COVID-19 patients. Conducted at Dr. Ziauddin Hospital, Karachi, from April to December 2020, the study included 532 hospitalized patients with confirmed COVID-19 diagnoses. Data were collected retrospectively following approval by the institutional ethics committee. Of the total patients, 408 (76.7%) with mild symptoms were admitted to the general ward, while 124 (23.3%) required intensive care. Among them, 150 patients (28.2%) died, and 382 (71.8%) were discharged home. Significant differences in biomarker levels were observed between survivors and non-survivors. The overall median (IQR) levels were LDH 434.00 (±328.75), Ferritin 765.50 (±1138.25), and D-Dimer 1564.00 (±5113.75). In discharged patients, median LDH was 389.00, Ferritin 622.50, and D-Dimer 1235.00, whereas in deceased patients, the corresponding values were 576.00, 1027.00, and 3885.50. Elevated LDH was found in 141 (94.0%, p=0.17), elevated Ferritin in 121 (80.7%, p=0.00), and elevated D-Dimer in 137 (91.3%, p=0.00). These findings suggest that elevated levels of LDH, Ferritin, and D-Dimer are significant indicators of disease severity and mortality in COVID-19 patients and should be monitored closely and managed proactively to reduce the risk of adverse outcomes.
Published in | American Journal of Laboratory Medicine (Volume 10, Issue 3) |
DOI | 10.11648/j.ajlm.20251003.12 |
Page(s) | 58-63 |
Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
Copyright |
Copyright © The Author(s), 2025. Published by Science Publishing Group |
COVID-19, Ferritin, LDH, D-Dimer, Mortality
Age | Heart Rate | Temperature | Respiratory Rate | SpO2 | Systolic Blood Pressure | Diastolic Blood Pressure | COVID-19 PCR | LDH | Ferriten | D-Dimer | |
---|---|---|---|---|---|---|---|---|---|---|---|
VALID | 532 | 532 | 331 | 532 | 532 | 532 | 532 | 532 | 532 | 532 | 532 |
MISSING | 0 | 0 | 201 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
MEAN | 56.66 | 103.5113 | 99.1876 | 23.6147 | 97.7008 | 129.51 | 78.1259 | 615.7756 | 1663.325 | 74254.52 | |
MEDIAN | 58 | 98 | 98 | 21 | 90 | 130 | 80 | 434 | 765.5 | 1564 | |
Std. DEVIATION | 14.791 | 60.032 | 71.99442 | 14.35454 | 98.67046 | 24.201 | 14.33107 | 897.2262 | 3810.798 | 211441.4 | |
RANGE | 85 | 1123 | 981 | 264 | 986 | 218 | 133 | 13169 | 43745 | 714900 | |
MIN | 10 | 53 | 10 | 16 | 2 | 12 | 37 | 21 | 15 | 100 | |
MAX | 95 | 1176 | 991 | 280 | 991 | 230 | 170 | 13190 | 43760 | 715000 |
Mortality (+) | Mortality (-) | Total | |
---|---|---|---|
LDH Elevated | 141 (TP) | 343 (FP) | 484 |
LDH Normal | 9 (FN) | 39 (TN) | 48 |
Total | 150 | 382 | 532 |
Mortality (+) | Mortality (-) | Total | |
---|---|---|---|
Ferritin Elevated | 121 (TP) | 249 (FP) | 370 |
Ferritin Normal | 29 (FN) | 133 (TN) | 162 |
Total | 150 | 382 | 532 |
Mortality (+) | Mortality (-) | Total | |
---|---|---|---|
D-Dimer Elevated | 137 (TP) | 293 (FP) | 430 |
D-Dimer Normal | 13 (FN) | 89 (TN) | 102 |
Total | 150 | 382 | 532 |
LDH | Lactate Dehydrogenase |
ICU | Intensive Care Unit |
ESR | Erythrocytes sedimentation rate |
CRP | C- Reactive Protein |
PCT | Procalcitonin |
CXR | Chest X-rays |
IQR | Interquartile Range |
PPV | Positive Predictive Value |
NPV | Negative Predictive Value |
[1] | Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X and Peng Z. Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020. |
[2] | Eurosurveillance Editorial T. Note from the editors: World Health Organization declares novel coronavirus (2019-nCoV) sixth public health emergency of international concern. Euro Surveill. 2020; 25. |
[3] | Mattiuzzi C, Lippi G. Which lessons shall we learn from the 2019 novel coronavirus outbreak? Ann Transl Med 2020; 8(03): 48. |
[4] | Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y. and Zhao, Y., 2020. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. Jama, 323(11), pp. 1061-1069. |
[5] | Lippi G, Favaloro EJ. Laboratory hemostasis: from biology to the bench. Clin Chem Lab Med 2018; 56(07): 1035-1045. |
[6] | Rodriguez-Morales AJC-O, J. A.; Gutiérrez-Ocampo, E.; Villamizar-Peña, R.; Holguin-Rivera, Y.; Escalera-Antezana, J. P.; Alvarado-Arnez, L. E.; Bonilla-Aldana, D. K.; Franco-Paredes, C.; Henao-Martinez, A. F.; Paniz-Mondolfi, A.; Lagos-Grisales, G. J.; Ramírez-Vallejo, E.; Suárez, J. A.; Zambrano, L. I.; Villamil-Gómez, W. E.; Balbin-Ramon, G. J.; Rabaan, A. A.; Harapan, H.; Dhama, K.; Nishiura, H.; Kataoka, H.; Ahmad, T.; Sah, R.. Clinical, Laboratory and Imaging Features of COVID-19: A Systematic Review and Meta-analysis. Preprints 2020, 2020020378 |
[7] | Zhou, B., She, J., Wang, Y. and Ma, X., 2020. Utility of ferritin, procalcitonin, and C-reactive protein in severe patients with 2019 novel coronavirus disease. |
[8] | Li, X., Wang, L., Yan, S., Yang, F., Xiang, L., Zhu, J., Shen, B. and Gong, Z., 2020. Clinical characteristics of 25 death cases with COVID-19: a retrospective review of medical records in a single medical center, Wuhan, China. International Journal of Infectious Diseases. |
[9] | Zhao, D., Yao, F., Wang, L., Zheng, L., Gao, Y., Ye, J., Guo, F., Zhao, H. and Gao, R., 2020. A comparative study on the clinical features of COVID-19 pneumonia to other pneumonias. Clinical Infectious Diseases. |
[10] | Mehta, P., McAuley, D. F., Brown, M., Sanchez, E., Tattersall, R. S., Manson, J. J. and HLH Across Speciality Collaboration, 2020. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet (London, England), 395(10229), p. 1033. |
[11] | Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X. and Cheng, Z., 2020. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet, 395(10223), pp. 497-506. |
[12] | Lechien, J. R., Chiesa-Estomba MD, C. M., Hans, S., Barillari MD, M. R., Jouffe, L. and Saussez, S., 2020. Loss of Smell and Taste in 2013 European Patients With Mild to Moderate COVID-19. Annals of Internal Medicine. |
[13] | Qasim, M., Ahmad, W., Zhang, S., Yasir, M. and Azhar, M., 2020. Data model to predict prevalence of COVID-19 in Pakistan. medRxiv. |
[14] | Shah, S. T. A., Iftikhar, A., Khan, M. I., Mansoor, M., Mirza, A. F. and Bilal, M., 2020. Predicting Covid-19 Infections Prevalence using Linear Regression Tool. Dr. Kuldeep Dhama, p. 1. |
[15] | Wilson, W., Raj, J. P., Rao, S., Ghiya, M., Nedungalaparambil, N. M., Mundra, H. and Mathew, R., 2020. Prevalence and predictors of stress, anxiety, and depression among healthcare workers managing COVID-19 pandemic in India: a nationwide observational study. Indian Journal of Psychological Medicine, 42(4), pp. 353-358. |
[16] | Assiri A, Al-Tawfiq JA, Al-Rabeeah AA, Al-Rabiah FA, Al-Hajjar S, Al-Barrak A, et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis. 2013; 13(9): 752-61. |
[17] | Oner AF, Bay A, Arslan S, Akdeniz H, Sahin HA, Cesur Y, et al. Avian influenza a (H5N1) infection in eastern Turkey in 2006. New Engl J Med. 2006; 355(21): 2179-85. |
[18] | Hoeboer SH, Oudemans-van Straaten HM, Groeneveld AJ. Albumin rather than Creactive protein may be valuable in predicting and monitoring the severity and course of acute respiratory distress syndrome in critically ill patients with or at risk for the syndrome after new onset fever. BMC Pulm Med. 2015; 15(1): 22. |
[19] | Li Y, Hu Y, Yu J, Ma T. Retrospective analysis of laboratory testing in 54 patients with severe- or critical-type 2019 novel coronavirus pneumonia. Lab Invest. 2020; 100: 794- 800. |
[20] | Baraboutis IG, Gargalianos P, Aggelonidou E, Adraktas A. Initial real-life experience from a designated COVID-19 Centre in Athens, Greece: a proposed therapeutic algorithm. SN Compr Clin Med. 2020; 1- 5. |
[21] | Velavan TP, Meyer CG. Mild versus severe COVID-19: laboratory markers. Int J Infect Dis. 2020; 95: 304- 307. |
[22] | Giamarellos-Bourboulis EJ, Netea MG, Rovina N, et al. Complex immune dysregulation in COVID-19 patients with severe respiratory failure. Cell Host Microbe. 2020; 27: 992- 1000. e1003. |
[23] | Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395: 1054- 1062. |
[24] | Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Int Med. 2020; 180(7): 934- 943. |
[25] | Kernan KF, Carcillo JA. Hyperferritinemia and inflammation. Int Immunol. 2017; 29: 401- 409. |
[26] | Dimopoulos G, de Mast Q, Markou N, et al. Favorable anakinra responses in severe covid-19 patients with secondary hemophagocytic lymphohistiocytosis. Cell Host Microbe. 2020; 28: 117- 123. e111. |
[27] | Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA. 2020 Aug 25; 324(8): 782-93. |
[28] | World Health Organization. Report of the WHO-China joint mission on coronavirus disease 2019 COVID-19 report. World Health Organization; 2020. |
[29] | Sproston NR, Ashworth JJ, et al. Role of C-Reactive Protein at Sites of Inflammation and Infection. Front Immunol. 2018; 9: 754. |
APA Style
Sami, A., Khan, I. A., Aghai, S. H., Faridi, A., Mohsin, S. N. (2025). Ldh Ferritin & D-Dimer Levels as Predictor of Mortality in COVID-19 Patients. American Journal of Laboratory Medicine, 10(3), 58-63. https://doi.org/10.11648/j.ajlm.20251003.12
ACS Style
Sami, A.; Khan, I. A.; Aghai, S. H.; Faridi, A.; Mohsin, S. N. Ldh Ferritin & D-Dimer Levels as Predictor of Mortality in COVID-19 Patients. Am. J. Lab. Med. 2025, 10(3), 58-63. doi: 10.11648/j.ajlm.20251003.12
@article{10.11648/j.ajlm.20251003.12, author = {Abdul Sami and Inayat Ali Khan and Salva Hafeez Aghai and Arsala Faridi and Syed Naveed Mohsin}, title = {Ldh Ferritin & D-Dimer Levels as Predictor of Mortality in COVID-19 Patients }, journal = {American Journal of Laboratory Medicine}, volume = {10}, number = {3}, pages = {58-63}, doi = {10.11648/j.ajlm.20251003.12}, url = {https://doi.org/10.11648/j.ajlm.20251003.12}, eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajlm.20251003.12}, abstract = {This single-center observational study aimed to evaluate the accuracy of LDH, Ferritin, and D-Dimer levels as early predictors of mortality in COVID-19 patients. Conducted at Dr. Ziauddin Hospital, Karachi, from April to December 2020, the study included 532 hospitalized patients with confirmed COVID-19 diagnoses. Data were collected retrospectively following approval by the institutional ethics committee. Of the total patients, 408 (76.7%) with mild symptoms were admitted to the general ward, while 124 (23.3%) required intensive care. Among them, 150 patients (28.2%) died, and 382 (71.8%) were discharged home. Significant differences in biomarker levels were observed between survivors and non-survivors. The overall median (IQR) levels were LDH 434.00 (±328.75), Ferritin 765.50 (±1138.25), and D-Dimer 1564.00 (±5113.75). In discharged patients, median LDH was 389.00, Ferritin 622.50, and D-Dimer 1235.00, whereas in deceased patients, the corresponding values were 576.00, 1027.00, and 3885.50. Elevated LDH was found in 141 (94.0%, p=0.17), elevated Ferritin in 121 (80.7%, p=0.00), and elevated D-Dimer in 137 (91.3%, p=0.00). These findings suggest that elevated levels of LDH, Ferritin, and D-Dimer are significant indicators of disease severity and mortality in COVID-19 patients and should be monitored closely and managed proactively to reduce the risk of adverse outcomes. }, year = {2025} }
TY - JOUR T1 - Ldh Ferritin & D-Dimer Levels as Predictor of Mortality in COVID-19 Patients AU - Abdul Sami AU - Inayat Ali Khan AU - Salva Hafeez Aghai AU - Arsala Faridi AU - Syed Naveed Mohsin Y1 - 2025/08/28 PY - 2025 N1 - https://doi.org/10.11648/j.ajlm.20251003.12 DO - 10.11648/j.ajlm.20251003.12 T2 - American Journal of Laboratory Medicine JF - American Journal of Laboratory Medicine JO - American Journal of Laboratory Medicine SP - 58 EP - 63 PB - Science Publishing Group SN - 2575-386X UR - https://doi.org/10.11648/j.ajlm.20251003.12 AB - This single-center observational study aimed to evaluate the accuracy of LDH, Ferritin, and D-Dimer levels as early predictors of mortality in COVID-19 patients. Conducted at Dr. Ziauddin Hospital, Karachi, from April to December 2020, the study included 532 hospitalized patients with confirmed COVID-19 diagnoses. Data were collected retrospectively following approval by the institutional ethics committee. Of the total patients, 408 (76.7%) with mild symptoms were admitted to the general ward, while 124 (23.3%) required intensive care. Among them, 150 patients (28.2%) died, and 382 (71.8%) were discharged home. Significant differences in biomarker levels were observed between survivors and non-survivors. The overall median (IQR) levels were LDH 434.00 (±328.75), Ferritin 765.50 (±1138.25), and D-Dimer 1564.00 (±5113.75). In discharged patients, median LDH was 389.00, Ferritin 622.50, and D-Dimer 1235.00, whereas in deceased patients, the corresponding values were 576.00, 1027.00, and 3885.50. Elevated LDH was found in 141 (94.0%, p=0.17), elevated Ferritin in 121 (80.7%, p=0.00), and elevated D-Dimer in 137 (91.3%, p=0.00). These findings suggest that elevated levels of LDH, Ferritin, and D-Dimer are significant indicators of disease severity and mortality in COVID-19 patients and should be monitored closely and managed proactively to reduce the risk of adverse outcomes. VL - 10 IS - 3 ER -